Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.
|Journal||Journal of Clinical Medicine|
|State||Published - May 1 2022|
Bibliographical noteFunding Information:
Conflicts of Interest: J.K. has received funding from Ipsen for research related to clinical trial NCT04088786. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. All other authors declare no conflict of interest.
This research was funded by NIH Training Grant T32CA160003 (M.M.H.).
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- appendiceal cancer
- colorectal cancer
- cytoreductive surgery (CRS)
- hyperthermic intraperitoneal chemotherapy (HIPEC)
- peritoneal carcinomatosis
- peritoneal surface malignancies (PSM)
ASJC Scopus subject areas
- Medicine (all)